Asset Details
Do you wish to reserve the book?
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Do you wish to request the book?
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
2017
Overview
In three phase 3 trials involving patients with ulcerative colitis, tofacitinib (an oral, small-molecule Janus kinase inhibitor) was more effective as induction and maintenance therapy than placebo. Infections were more common with tofacitinib.
Ulcerative colitis is characterized by an increased frequency of bowel movements and bloody diarrhea, which has a negative effect on quality of life.
1
Current therapies for ulcerative colitis include mesalamine, glucocorticoids, thiopurines, and antagonists to tumor necrosis factor (TNF) and α4β7 integrin.
1
–
5
Many patients do not have a response to these therapies or have a response that is not sustained. Additional treatment options with new mechanisms of action are needed to increase efficacy rates.
The Janus kinase (JAK) family comprises four intracellular tyrosine kinases — JAK1, JAK2, JAK3, and nonreceptor tyrosine-protein kinase 2 — that activate signal transducers and . . .
Publisher
Massachusetts Medical Society
Subject
/ Colitis, Ulcerative - drug therapy
/ Colon
/ Female
/ Humans
/ Janus Kinases - antagonists & inhibitors
/ Male
/ Piperidines - adverse effects
/ Piperidines - pharmacokinetics
/ Piperidines - therapeutic use
/ Protein Kinase Inhibitors - adverse effects
/ Protein Kinase Inhibitors - pharmacokinetics
/ Protein Kinase Inhibitors - therapeutic use
/ Pyrimidines - adverse effects
/ Pyrimidines - pharmacokinetics
